Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: A meta-analysis of the published literature

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Su, Yuan ^a   Yang, Wei Bing ^a   Li, Shi ^a   Ye, Zhi Jian ^a   Shi, Huan Zhong ^a   Zhou, Qiong ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; HUMAN; KIDNEY CARCINOMA; LIVER CANCER; LOW DRUG DOSE; LUNG CANCER; META ANALYSIS; MONOTHERAPY; NEOPLASM; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; SURVIVAL RATE; FACTUAL DATABASE; MORTALITY; PROPORTIONAL HAZARDS MODEL; RISK;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DATABASES, FACTUAL; HUMANS; NEOPLASMS; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 84859958002     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035629     Document Type: Article

References (98)

1. Kerbel RS, (2008) Tumor angiogenesis. N Engl J Med 358: 2039-2049.
2. Hicklin DJ, Ellis LM, (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027.
3. Gerber HP, Ferrara N, (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65: 671-680.
4. Van Meter ME, Kim ES, (2010) Bevacizumab: current updates in treatment. Curr Opin Oncol 22: 586-591.
5. Gressett SM, Shah SR, (2009) Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 43: 490-501.
6. Ranpura V, Hapani S, Wu S, (2011) Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305: 487-494.
7. Jiang J, Shi HZ, Deng JM, Liang QL, Qin SM, et al. (2009) Efficacy of intensified chemotherapy with hematopoietic progenitors in small-cell lung cancer: a meta-analysis of the published literature. Lung Cancer 65: 214-218.
8. Parmar MK, Torri V, Stewart L, (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834.
9. Higgins JP, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
10. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
11. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, et al. (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184-2191.
12. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550.
13. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, et al. (2007) Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25: 4743-4750.
14. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, et al. (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27: 1227-1234.
15. Brahmer JR, Dahlberg SE, Gray RJ, Schiller JH, Perry MC, et al. (2011) Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599. J Thorac Oncol 6: 103-108.
16. Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, et al. (2011) Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 377: 1846-1854.
17. Spigel DR, Townley PM, Waterhouse DM, Fang L, Adiguzel I, et al. (2011) Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 29: 2215-2222.
18. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
19. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, et al. (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23: 3697-3705.
20. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, et al. (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544.
21. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, et al. (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013-2019.
22. Moehler M, Sprinzl MF, Abdelfattah M, Schimanski CC, Adami B, et al. (2009) Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol 15: 449-456.
23. Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, et al. (2010) Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 28: 3191-3198.
24. Stathopoulos GP, Batziou C, Trafalis D, Koutantos J, Batzios S, et al. (2010) Treatment of Colorectal Cancer with and without Bevacizumab: A Phase III Study. Oncology 78: 376-381.
25. Kemeny NE, Jarnagin WR, Capanu M, Fong Y, Gewirtz AN, et al. (2011) Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol 29: 884-889.
26. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, et al. (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792-799.
27. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676.
28. Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, et al. (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28: 3239-3247.
29. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, et al. (2011) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29: 4286-4293.
30. Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, et al. (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29: 1252-1260.
31. Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, et al. (2011) Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 12: 369-376.
32. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434.
33. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, et al. (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103-2111.
34. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, et al. (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26: 5422-5428.
35. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, et al. (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27: 2231-2237.
36. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, et al. (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28: 3617-3622.
37. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, et al. (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365: 2473-2483.
38. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, et al. (2011) A Phase 3 Trial of Bevacizumab in Ovarian Cancer. N Engl J Med 365: 2484-2496.
39. Kemeny NE, Schwartz L, Gönen M, Yopp A, Gultekin D, et al. (2011) Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology 80: 153-159.
40. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, et al. (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29: 3968-3976.
41. Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, et al. (2006) Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 24: 217-227.
42. Kabbinavar FF, Wallace JF, Holmgren E, Yi J, Cella D, et al. (2008) Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. Oncologist 13: 1021-1029.
43. Melichar B, Koralewski P, Ravaud A, Pluzanska A, Bracarda S, et al. (2008) First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 19: 1470-1476.
44. Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, et al. (2008) Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 26: 60-65.
45. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL, (2009) Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 27: 4966-72.
46. Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O, (2009) The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 14: 22-28.
47. Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, et al. (2009) Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomized phase-III NO16966 trial. Br J Cancer 101: 1033-1038.
48. Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, et al. (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28: 2144-2150.
49. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, et al. (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28: 2137-2143.
50. Mok TS, Hsia TC, Tsai CM, Tsang K, Chang GC, et al. (2011) Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial. Asia Pac J Clin Oncol 7 (Suppl 2): 4-12.
51. Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, et al. (2011) Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. J Clin Oncol 29: 2675-2682.
52. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, et al. (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65.
53. Price N, (2004) Bevacizumab improves the efficacy of 5-fluorouracil/leucovorin in patients with advanced colorectal cancer. Clin Colorectal Cancer 4: 89-91.
54. Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL, et al. (2004) Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 10: 2584-2586.
55. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, et al. (2005) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23: 3502-3508.
56. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, et al. (2005) Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23: 3706-3712.
57. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, et al. (2008) Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 26: 3523-3529.
58. Stein WD, Yang J, Bates SE, Fojo T, (2008) Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist 13: 1055-1062.
59. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Colangelo LH, et al. (2009) Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 27: 3385-3390.
60. Robertson JD, Botwood NA, Rothenberg ML, Schmoll HJ, (2009) Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. Clin Colorectal Cancer 8: 59-60.
61. Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, et al. (2010) Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28: 2070-2076.
62. Pivot X, Schneeweiss A, Verma S, Thomssen C, Passos-Coelho JL, et al. (2011) Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. Eur J Cancer 47: 2387-2395.
63. Salama JK, Haraf DJ, Stenson KM, Blair EA, Witt ME, et al. (2011) A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol 22: 2304-2309.
64. Soria JC, Márk Z, Zatloukal P, Szima B, Albert I, et al. (2011) Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol 29: 4442-4451.
65. Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, et al. (2011) Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 117: 5351-5358.
66. Reardon DA, Desjardins A, Peters K, Gururangan S, Sampson J, et al. (2011) Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol 103: 371-379.
67. Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, et al. (2011) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79: 1487-1495.
68. Pope WB, Lai A, Mehta R, Kim HJ, Qiao J, et al. (2011) Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol 32: 882-889.
69. Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, et al. (2011) Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. J Clin Oncol 29: 2675-2682.
70. Varker KA, Biber JE, Kefauver C, Jensen R, Lehman A, et al. (2007) A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 14: 2367-2376.
71. Di Lorenzo G, Figg WD, Fossa SD, Mirone V, Autorino R, et al. (2008) Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 54: 1089-1094.
72. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, et al. (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733-4740.
73. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, et al. (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27: 672-680.
74. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, et al. (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360: 563-72.
75. Kreisl TN, Zhang W, Odia Y, Shih JH, Butman JA, et al. (2011) A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol 13: 1143-1150.
76. Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE, et al. (2011) The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 17: 4119-4124.
77. Blumenschein GR Jr, Kabbinavar F, Menon H, Mok TS, Stephenson J, et al. (2011) A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol 22: 2057-2067.
78. Chang JW, Thongprasert S, Wright E, Tsang K, Kim HT, et al. (2011) An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia. Asia Pac J Clin Oncol 7 (Suppl 2): 13-21.
79. Chang GC, Ahn MJ, Wright E, Kim HT, Kim JH, et al. (2011) Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes. Asia Pac J Clin Oncol 7, (Suppl 2): 34-40.
80. Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, et al. (2011) A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer 117: 526-533.
81. McGonigle KF, Muntz HG, Vuky J, Paley PJ, Veljovich DS, et al. (2011) Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer 117: 3731-3740.
82. Zhi J, Chen E, Major P, Burns I, Robinson B, et al. (2011) A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 68: 1199-1206.
83. Moroney JW, Schlumbrecht MP, Helgason T, Coleman RL, Moulder S, et al. (2011) A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res 17: 6840-6846.
84. Négrier S, Gravis G, Pérol D, Chevreau C, Delva R, et al. (2011) Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 12: 673-680.
85. Rastogi P, Buyse ME, Swain SM, Jacobs SA, Robidoux A, et al. (2011) Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. Clin Breast Cancer 11: 228-234.
86. Yardley DA, Raefsky E, Castillo R, Lahiry A, Locicero R, et al. (2011) Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer. Clin Breast Cancer 11: 297-305.
87. Sehgal R, Lembersky BC, Rajasenan KK, Crandall TL, Balaban EP, et al. (2011) A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer. Clin Colorectal Cancer 10: 117-120.
88. Wong NS, Fernando NH, Bendell JC, Morse MA, Blobe GC, et al. (2011) A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer 10: 210-216.
89. Grignol VP, Olencki T, Relekar K, Taylor C, Kibler A, et al. (2011) A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma. J Immunother 34: 509-515.
90. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
91. Shih T, Lindley C, (2006) Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28: 1779-1802.
92. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, et al. (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99: 1232-1239.
93. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S, (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300: 2277-2285.
94. Hapani S, Chu D, Wu S, (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10: 559-568.
95. Wu S, Kim C, Baer L, Zhu X, (2010) Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 21: 1381-1389.
96. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S, (2010) Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 23: 460-468.
97. Cortes J, Calvo V, Ramírez-Merino N, O'Shaughnessy J, Brufsky A, et al. (2011) Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol 2011 Oct 4 [Epub ahead of print] PubMed PMID: 21976387.
98. Clarke MJ, Stewart LA, (2001) Obtaining individual patient data from randomized controlled trials, In: Egger M, Smith GD, Altman DG, editors. Systematic Reviews in Health Care London, UK BMJ Publishing Group, 2001:109-21 pp. 109-21.